# Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

> **NCT05683860** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wave Life Sciences Ltd.** · enrollment: 8 (actual)

## Conditions studied

- ALS
- FTD

## Interventions

- **DRUG:** WVE-004

## Key facts

- **NCT ID:** NCT05683860
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-14
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Despite robust, sustained reductions in poly(GP), no clinical benefit was seen at 24 weeks, and reductions in poly(GP) were not associated with stabilization in functional outcomes. Based on these data, Wave decided to stop development of WVE-004.
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683860, "Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05683860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*